GH1 and cardiomyopathy: Our data suggest that, insofar as (at least) physical frailty in tasks of relative performance is considered, lower GH signaling may not be detrimental; which, considering GH’s troubling cardiohypertrophic and tumorigenic potentials, and the increased susceptibility of aged organisms to cardiomyopathies [63] and cancer [64], argues against GH treatment of the elderly.